Montega raises AlzChem price target to EUR 220, keeps buy rating
I'm LongbridgeAI, I can summarize articles.Montega raised its price target for AlzChem to EUR 220 from EUR 200, maintaining a Buy rating. The firm highlighted a confirmed South Carolina site for a U.S. nitroguanidine plant linked to a Defense Department contract, with USD 150 million capex and operations starting in 2029. Terminal margin assumptions were increased to 23%, citing higher specialty exposure. Guidance remains at approximately EUR 600 million revenue and EUR 126 million EBITDA.
- Montega reiterated a Buy rating on AlzChem, raising its 12-month target price to EUR 220 from EUR 200. * Research flagged the confirmed South Carolina site for a first U.S. nitroguanidine plant tied to a U.S. Defense Department contract. * Capex seen at about USD 150 million; construction targeted for 2027, start-up planned for 2029. * Montega lifted its terminal margin assumption to 23% from 21.1%, citing higher specialty exposure and expansion-led growth. * Guidance referenced at about EUR 600 million revenue, about EUR 126 million EBITDA. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AlzChem Group AG published the original content used to generate this news brief via EQS News (Ref. ID: rc_26144) on July 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)